EFS and OS in patients with NPM1-mutated and no FLT3-ITD AML (favorable genotype) versus other patients, according to the presence of a normal karyotype or not. In the presence of NPM1 mutation and no FLT3-ITD (favorable genotype), estimated 5-year EFS was 41% (95% CI, 29%-54%) in the 79 patients with CN-AML (green curves) and 19% (95% CI, 5%-40%) in the 16 patients with non-CBF abnormal karyotype (blue curves; P = .04). In these patients, estimated 5-year OS was 51% (95% CI, 36%-64%) in CN-AML patients and 31% (95% CI, 10%-55%) in the non-CBF CA-AML patients (P = .12). In the absence of this favorable genotype, estimated 5-year EFS was 19% (95% CI, 13%-26%) in the 188 patients with CN-AML (yellow curves) and 16% (95% CI, 11%-23%) in the 197 patients with non-CBF abnormal karyotype (red curves; P = .13). In these patients, estimated 5-year OS was 30% (95% CI, 21%-36%) in CN-AML patients and 27% (95% CI, 20%-35%) in the non-CBF CA-AML patients (P = .10). As shown, a favorable genotype was thus predictive of a longer EFS and OS in patients with CN-AML (P < .001 and P = .001, respectively), but not in those with non-CBF CA-AML (P = .38 and P = .36, respectively).